The focus initially will be the previously-approved indication for adolescent obesity along with new treatment areas non-alcoholic fatty liver disease and for non-alcoholic steatohepatitis.
M Pharma’s C-103 is a combination of orlistat, simethicone (which reduces bloating) and activated charcoal.
Together they work to mitigate the bowel-related problems with a product that otherwise has a clean bill of health.
Orlistat is the best-selling weight loss medication of all time with peak sales of over $900mln. It has a strong safety profile and is approved by the US Food & Drug Administration.
According to the World Health Organization, 1.9bn adults globally are overweight or obese, which adds up to a ticking healthcare time-bomb.
“Obesity increases the risk of heart disease, diabetes, kidney complications, joint disorders and certain cancers,” said M Pharma chief executive Gary Thompson.
“M Pharma has a unique opportunity with C-103 to make a significant impact in treating this world epidemic.”
Story by ProactiveInvestors